Bragar Eagel & Squire, P.C. Reminds Investors That Class

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
238
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intelligent Systems, Helius Medical, Verb Technology, and CannTrust and Encourages Investors to Contact the Firm

NEW YORK, Aug. 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Intelligent Systems Corporation (NYSE: INS), Helius Medical Technologies, Inc. (NASDAQ: HASDT), Verb Technology Company, Inc. (NASDAQ: VERB), and CannTrust Holdings, Inc. (NYSE: CTST). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Intelligent Systems Corporation (NYSE: INS)

Lead Plaintiff Deadline: September 9, 2019

Class Period: January 23, 2019 to May 29, 2019

The complaint, filed on July 9, 2019, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Petit, the “financial expert” on Intelligent Systems’ Audit Committee engaged in accounting fraud as the CEO of MiMedx Group, Inc.; (2) Intelligent Systems’ CEO, Defendant Strange, engaged in undisclosed related-party transactions with Defendant Petit and others and had an undisclosed personal relationship with the Company’s auditor; (3) Intelligent Systems had its employees set up or take control of shell companies in Asia so they could partake in undisclosed related-party transactions for the purpose of either fabricating revenue for the Company and/or siphoning money out of the Company; and (4) as a result, defendants’ statements about Intelligent Systems’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

For more information on the Intelligent Systems class action go to: https://bespc.com/INS

Helius Medical Technologies (NASDAQ: HSDT)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 9, 2017 to April 10, 2019

The complaint, filed on July 9, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the clinical study on the use of PoNS did not produce statistically significant results regarding the effectiveness of the treatment; (2) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; (3) that, as a result, the Company was unlikely to receive regulatory approval of PoNS; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Helius class action go to: https://bespc.com/HSDT

Verb Technology Company, Inc. (NASDAQ: VERB)

Lead Plaintiff Deadline: September 9, 2019

Class Period: January 3, 2018 to May 2, 2018

The complaint, filed on July 9, 2019, alleges that during the Class Period Verb stock increased from approximately $0.12 per share on January 3, 2018 to $2.70 per share on April 19, 2018, an astonishing increase of over 2000%.

Following the rapid rise of the Company’s stock price, on April 23, 2018, the truth as to the Company’s relationship with Oracle began to emerge. The Company revealed the actual terms of the Oracle Agreement through the filing of a Form 8-K. The terms of the agreement revealed that the prior representations as to the scope of the relationship with Oracle were materially misleading.

As the market digested the true nature of the Oracle Agreement, the stock began a precipitous decline, closing on April 30, 2018 at $1.54 per share, a decrease of 43% from the high a week prior.  The market continued to digest this information and by the market close on May 2, 2018, the Company’s stock was trading at $1.08 per share, a decrease of 64% from the high price of $3.04 per share on April 20 th .

For more information on the Verb Technology class action go to: https://bespc.com/verb

CannTrust Holdings, Inc. (NYSE: CTST)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 14, 2018 to July 12, 2019

The complaint, filed on July 10, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) that the Company’s Pelham greenhouse did not comply with certain regulations; (3) that, as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) that, as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the CannTrust class action go to: https://bespc.com/ctst

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com .  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 545

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 791

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 526

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 112

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 129

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 188

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 190

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 138

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 40

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 309

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Volvo Ends LiDAR Partnership: What This Means for LAZR Stock

Updated Category News Views 315

Volvo's Shift Away from LiDAR Technology Recently, the Swedish automaker Volvo announced its decision to cease its partnership with Luminar Technologies Inc. (NASDAQ: LAZR). This bold move has caught the attention of the automotive industry, especially those tracking advancements in autonomous vehicle technology. By not integrating LiDAR technology into its forthcoming...

Continue Reading
Samsung and Xiaomi Face Antitrust Findings in India Market

Updated Category News Views 157

Samsung and Xiaomi Face Antitrust Investigation in India Samsung, Xiaomi, and various other smartphone manufacturers are under serious scrutiny for allegedly colluding with major e-commerce platforms in India, undermining fair market practices. The Competition Commission of India (CCI) has gathered evidence that suggests these companies coordinated with Amazon and...

Continue Reading
Bonnie Navin Honored as Top 25 Medical Malpractice Attorney

Updated Category News Views 164

Bonnie Navin Attributes and Accolades Bonnie Navin of Rubenstein Law has recently earned a significant honor by being selected as a member of the Medical Malpractice Trial Lawyers Association - Top 25. This elite recognition is awarded to the most distinguished attorneys specializing in medical malpractice across the nation, and it showcases Navin's exceptional skill and...

Continue Reading
Top Dividend Stocks for Long-Term Passive Income Investors

Updated Category News Views 99

Success in the business world has never been a cakewalk. Many new ventures stumble within a decade, and only a handful manage to stay afloat while also boasting a robust and growing dividend program. Companies that consistently dish out dividends reflect financial health, but there’s more to the story. Take Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE:...

Continue Reading
Cathie Wood Predicts Deflationary Boom Amid Market Decline

Updated Category News Views 404

Cathie Wood's Deflationary Boom Forecast Amid Market Turbulence CEO of Ark Funds, Cathie Wood, has made bold predictions regarding a potential "deflationary boom" despite significant losses in the stock market. Recent trading sessions saw renowned tech stocks, collectively known as the Magnificent Seven, lose about $780 billion in market capitalization in a single day,...

Continue Reading